If I had to guess, the complexity of the situation is prolonging partnership/deal negotiations. Immediately on the table is trial 3 for one indication, but at the same time, the same molecule has nascent indicative data for much greater possibilities.
What to include, what not to, with what model and at what price.
That’s a lot of puzzle pieces for the team.
11 Likes